Current developments in personalized medicine enhance safety and tolerability of drug treatment in HNSCC, suggesting integration of biomarkers in therapy.
The future of HNSCC treatment lies in the development of novel treatment combinations integrating immunotherapy using immune checkpoint blockade with newer therapeutic approaches. Understanding which agents to use, and when in the course of treatment, stands as a challenge that will shape the future of precision therapy for HNSCC, with integration of biomarkers promising to guide this transition.
No takes yet. Share an insight, caveat, or question.
Champlin et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: